Lexeo Raises $100m To Advance CNS Candidates, Validate Cardiac Gene Therapies

Start-Up Has Brought In $185m In Less Than A Year

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.

Gene therapy concept vector illustration
Lexeo will take its first gene therapy for a rare cardiomyopathy into the clinic within the next few months • Source: Alamy

Lexeo Therapeutics has accomplished a lot in the nine months since it launched with $85m in series A venture capital for development of AAV-mediated gene therapies that treat rare and prevalent monogenic central nervous system and cardiac diseases. And now, after acquiring four cardiomyopathy programs, the company has closed a $100m series B round to fund its two clinical-stage treatments for CNS diseases, pursue clinical validation for gene therapies in rare cardiac indications and advance its preclinical programs.

CEO R. Nolan Townsend told Scrip that he is encouraged by recent discussions about the safety of AAV-based gene therapies,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

spo

Akash test for clone

Test article to check the clone issue

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.